52 completed, 15 terminated, 7 unknown, 6 withdrawn. 46 Phase 1, 22 Phase 2, 8 Not applicable, 4 Phase 3, 3 Phase 4.
Follow Advanced Cancers: new trials by email Literature Review of Advanced Cancers trials Research Report on Advanced Cancers
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Clinical Trial of TQB2922 Injection (Subcutaneous Injection) in Patients With Advanced Cancers TQB2922 injection (subcutaneous injection) - Advanced Cancers | Phase 1 | Recruiting | Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. | 42 | 2025-12-16 | 2026-09-10 |
| A Multicenter, Open Label Phase I Clinical Trial Evaluating the Safety and Pharmacokinetics of TQB2252 Injection in Subjects With Advanced Malignant Tumors TQB2252 injection - Advanced Cancers | Phase 1 | Not yet recruiting | Chia Tai Tianqing Pharmaceutical (Guangzhou) Co., Ltd. | 100 | 2024-11-01 | 2024-10-21 |
| Psilocybin in Cancer Pain Study Psilocybin - Opioid-Related Disorders, Pain Management | Phase 2 | Active not recruiting | Yvan Beaussant, MD, MSci | 15 | 2024-09-23 | 2026-10-27 |
| A Clinical Study of TQB3107 Tablets in Patients With Malignant Tumors TQB3107 Tablets - Advanced Cancers | Phase 1 | Recruiting | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 140 | 2024-06-27 | 2026-07-29 |
| Clinical Trial of the TQB3602 Capsule Combined With AK105 Injection in Patients With Advanced Cancers TQB3602 Capsule + AK105 Injection - Advanced Cancers | Phase 1 | Unknown | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 7 | 2022-07-29 | 2023-07-27 |
| Clinical Trial of the TQB2930 Injection in Patients With Advanced Cancers TQB2930 injection - Advanced Cancers | Phase 1 | Unknown | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | 60 | 2022-05-01 | 2022-05-19 |
| Hepatic Impairment Study for Lorlatinib in Cancer Patients lorlatinib - Advanced Cancers | Phase 1 | Terminated | Pfizer | 1 | 2020-01-14 | 2024-06-21 |
| Plasmodium Immunotherapy for Advanced Cancers Blood-stage infection of P.vivax - Advanced Cancers | Phase 1 / Phase 2 | Unknown | CAS Lamvac Biotech Co., Ltd. | 20 | 2017-11-23 | 2024-02-20 |
| Art Therapy in Palliative Care: Study of Identification and Understanding of the Mechanisms of Change in the Patient art therapy - Psychological Stress, Suffering | Not applicable | Completed | Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau | 103 | 2016-10-20 | 2022-03-24 |
| A Study of LY2606368 (Prexasertib) in Patients With Solid Tumors With Replicative Stress or Homologous Repair Deficiency LY2606368 - Advanced Cancers | Phase 2 | Completed | Dana-Farber Cancer Institute | 27 | 2016-10-12 | 2022-10-21 |
| Phase II Study of Ilorasertib (ABT348) in Patients With CDKN2A Deficient Solid Tumors Ilorasertib - Advanced Cancers | Phase 2 | Terminated | M.D. Anderson Cancer Center | 12 | 2016-08-05 | 2023-07-17 |
| Ipilimumab (Immunotherapy) and MGN1703 (TLR Agonist) in Patients With Advanced Solid Malignancies MGN1703, Ipilimumab - Advanced Cancers, Melanoma | Phase 1 | Terminated | M.D. Anderson Cancer Center | 28 | 2016-05-11 | 2026-04-07 |
| Indwelling Pleural Catheter With Either Doxycycline or Saline at Day 7 for Pleurodesis Questionnaires, Fentanyl Patch, Fentanyl (IV) - Advanced Cancers, Malignant Pleural Effusions | Phase 4 | Terminated | M.D. Anderson Cancer Center | 3 | 2016-04-27 | 2019-08-07 |
| Sublingual Fentanyl for the Management of Breakthrough Pain Fentanyl Sublingual Spray (FSS), Questionnaires, Mental Ability Tests - Advanced Cancers | Phase 2 | Terminated | M.D. Anderson Cancer Center | 6 | 2016-02-02 | 2021-05-18 |
| Fentanyl Sublingual Spray for Exercise-Induced Breakthrough Dyspnea Fentanyl Sublingual Spray, Shuttle Walk Test, Questionnaires - Advanced Cancers | Phase 2 / Phase 3 | Completed | M.D. Anderson Cancer Center | 50 | 2016-01-04 | 2021-02-09 |
| Occupational Therapy in Palliative Care Questionnaire - Advanced Cancers | Not applicable | Terminated | M.D. Anderson Cancer Center | 86 | 2015-11-13 | 2020-01-13 |
| A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies DCC-2618 - Gastrointestinal Stromal Tumors, Advanced Systemic Mastocytosis | Phase 1 | Completed | Deciphera Pharmaceuticals, LLC | 282 | 2015-11-01 | 2023-12-13 |
| A Multiple Dose, Dose Escalation Trial of AEB1102 in Patients With Advanced Solid Tumors Co-ArgI-PEG - Advanced Cancers | Phase 1 | Completed | Immedica Pharma AB | 76 | 2015-10-22 | 2026-08-06 |
| Compare Fentanyl Nasal Spray With Intravenous Opioids to Treat Severe Pain Fentanyl Nasal Spray, Hydromorphone Hydrochloride, Phone Call - Advanced Cancers, Pain | Phase 4 | Completed | M.D. Anderson Cancer Center | 84 | 2015-09-14 | 2021-06-16 |
| Perception of Palliative Care Encounter Survey - Advanced Cancers | Completed | M.D. Anderson Cancer Center | 209 | 2015-08-16 | 2021-04-14 |
Showing 20 of 87. Sign in to see all of them.
Neoplasm Metastasis (14) · Neoplasms (8) · Dyspnea (6) · Melanoma (5) · Recurrence (5) · Lymphoma (4) · Breast Neoplasms (3) · Colorectal Neoplasms (3) · Lung Neoplasms (3) · Sarcoma (3) · Agnosia (2) · Death (2) · Fatigue (2) · Hematologic Diseases (2) · Hematologic Neoplasms (2)
Pathological Conditions, Signs and Symptoms (29) · Neoplasms (26) · Pathologic Processes (17) · Signs and Symptoms (15) · Neoplastic Processes (14) · Hemic and Lymphatic Diseases (11) · Neoplasms by Histologic Type (11) · Neoplasms by Site (11) · Respiratory Tract Diseases (11) · Immune System Diseases (7) · Digestive System Diseases (6) · Disease Attributes (6) · Immunoproliferative Disorders (6) · Lymphoproliferative Disorders (6) · Respiration Disorders (6)
Surveys and Questionnaires (22) · Bevacizumab (4) · Cetuximab (4) · Erlotinib Hydrochloride (4) · Vorinostat (4) · Albumin-Bound Paclitaxel (3) · Azacitidine (3) · Interviews as Topic (3) · Lenalidomide (3) · Oxaliplatin (3) · Sugars (3) · pazopanib (3) · temsirolimus (3) · 130-nm albumin-bound paclitaxel (2) · Calcium Dobesilate (2)
M.D. Anderson Cancer Center (69) · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (2) · British Columbia Cancer Agency (1) · CAS Lamvac Biotech Co., Ltd. (1) · Chia Tai Tianqing Pharmaceutical (Guangzhou) Co., Ltd. (1) · Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. (1) · China Medical University Hospital (1) · Dana-Farber Cancer Institute (1) · Deciphera Pharmaceuticals, LLC (1) · Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau (1) · Immedica Pharma AB (1) · Ionis Pharmaceuticals, Inc. (1) · Janssen Research & Development, LLC (1) · Merck Sharp & Dohme LLC (1) · Pfizer (1)
United States (71) · China (6) · Canada (2) · Spain (2) · France (1) · Germany (1) · Israel (1) · Italy (1) · Netherlands (1) · Taiwan (1) · United Kingdom (1)
David Hui, MD (8) · David S. Hong, MD (6) · Apostolia M. Tsimberidou, MD, PHD (5) · Filip Janku, MD, PHD (5) · Eduardo Bruera, MD (4) · Aung Naing, MD (3) · Siqing Fu, MD, PHD (3) · Funda Meric-Bernstam, MD (2) · Isabel Torres, MPH, DRPH (2) · Jennifer J. Wheler, MD (2) · Abdulla K. Salahudeen, MD (1) · Andrea Hayes-Jordan, MD (1) · Angelique N. Wong, MD (1) · Antonio Pascual, MD (1) · Apostolia M. Tsimberidou, MD, PhD (1)
PMID 21931708, PMID 22491798, PMID 23739633, PMID 23756764, PMID 23830530, PMID 24668327, PMID 24746841, PMID 26062823, PMID 26698868, PMID 27197177, PMID 27330023, PMID 27401508, PMID 28228842, PMID 28422758, PMID 28445973, PMID 28650446, PMID 28874596, PMID 28950338, PMID 28975307, PMID 29092957, PMID 30446007, PMID 30833417, PMID 31160355, PMID 31371350, PMID 31481506, PMID 31888672, PMID 31907737, PMID 32649717, PMID 32804590, PMID 33580845, PMID 35726793, PMID 39413348, PMID 39787747, PMID 39959251
1UL1RR024148 (1), 3UL1RR024148-04S1 (1), K01CA151785 (1), R21CA186000 (1)